RNAi Controls
Invitrogen™ Silencer™ Negative Control No. 1 siRNA
Silencer Negative Control No. 1 siRNA is a bioinformatically designed, non-targeting siRNA crucial for siRNA experiments. Matching Silencer chemistry, it is an essential negative control siRNA for achieving clear, accurate gene silencing results.
Invitrogen™ Anti-miR™ miRNA Inhibitor Negative Control #1
Anti-miR™ miRNA Inhibitor Negative Control #1
Invitrogen™ Silencer™ GAPDH Positive Control siRNA, in vivo ready
Ambion™ Silencer™ GAPDH Positive Control siRNA, In Vivo Ready is ideal for developing and optimizing siRNA experiments.
Invitrogen™ Stealth RNAi™ siRNA Negative Control Med GC Duplex #2
Stealth RNAi™ siRNA Negative Control Med GC Duplex #2
Invitrogen™ Silencer™ Negative Control No. 4 siRNA
Ambion™ Silencer™ Negative Control #4 siRNA has no significant sequence similarity to mouse, rat, or human gene sequences.
Invitrogen™ Pre-miR™ hsa-miR-1 miRNA Precursor Positive Control
The Pre-miR™ hsa-miR-1 miRNA Precursor is intended for use as a positive control in experiments utilizing Pre-miR miRNA Precursors.
Invitrogen™ Silencer™ Select Negative Control No. 1 siRNA, in vivo ready
Silencer™ Select Negative Control No. 1 siRNA, in vivo ready
Invitrogen™ Stealth RNAi™ siRNA Negative Control Hi GC Duplex #2
Stealth RNAi™ siRNA Negative Controls are a great way to measure the effect of your experimental Stealth RNAi™ siRNA duplex versus background.
Invitrogen™ Stealth RNAi™ siRNA Negative Control, Med GC
Stealth RNAi™ siRNA Negative Control, Med GC
Invitrogen™ Ambion™ In Vivo Factor VII Positive Control siRNA
Ambion™ In Vivo siRNAs are designed using the proven Silencer™ Select algorithm and incorporate chemical modifications for superior serum stability with in vivo delivery.
Genscript Corporation CD40/TNFRSF5 hFc Chimera Huma
CD40 is a costimulatory protein found on antigen presenting cells and is required for their activation The binding of CD154 (CD40L) on TH cells to CD40 activates antigen presenting cells and induces a variety of downstream effects CD40 molecule is a potential target for cancer immunotherapy There are number of completed and ongoing clinical trials where agonistic anti-CD40 monoclonal antibodies are employed to activate an anti-tumor T cell response via activation of dendritic cells
